Search

Displaying results 4161 - 4170 of 9694 in total
  1. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites.

  2. Drug

    Bromopyruvate

    go.drugbank.com/drugs/DB17135
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    WP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

  4. Drug

    Briquilimab

    go.drugbank.com/drugs/DB18136
    Investigational

    Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).

  5. Drug

    ATX-01

    go.drugbank.com/drugs/DB18141
    Investigational

    ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).

  6. Drug

    MTL-CEBPA

    go.drugbank.com/drugs/DB18143
    Investigational

    MTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.

  7. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  8. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

  9. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  10. Drug

    LYT-200

    go.drugbank.com/drugs/DB18179
    Investigational

    LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.